Vanda Wins U.S. Panel Backing for Sleep Drug for Blind
This article is for subscribers only.
Vanda Pharmaceuticals Inc. won the backing of U.S. advisers for an experimental drug to regulate the circadian rhythms of blind people to help them sleep.
Vanda’s medicine, known as tasimelteon, is effective and safe for use, advisers to the Food and Drug Administration said today in Silver Spring, Maryland. The medication, which the company has proposed calling Hetlioz, is supposed to help synchronize the body with a 24-hour cycle. The FDA isn’t required to follow the recommendations of its advisory panels.